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Summary
We investigated whether the occurrence of venous
thrombosis in young women who use oral contraceptives
might be explained by the factor V Leiden mutation, which
leads to resistance to activated protein C and enhances
susceptibility to thrombosis.
We compared 155 consecutive premenopausal women,
aged 15 to 49, who had developed deep venous thrombosis
in the absence of other underlying diseases, with 169
Population controls. The risk of thrombosis among users of
oral contraceptives was increased 4-fold (relative risk 3-8
[95% Cl 2-4-6-0]). The risk of thrombosis among carriers
of the mutation compared with non-carriers was increased
8-fold (7-9 [3-2-19-4]). Compared with women who did not
use oral contraceptives and were not carriers of the
mutation, the risk of thrombosis among those with both
risk factors was increased more than 30-fold (34-7
[7-8-154]).
Recalculation of population incidences from these
relative risks shows that the absolute risk of venous
thrombosis in young women who use oral contraceptives is
much larger when they carry the factor V Leiden mutation.
When a young woman develops thrombosis, her factor V
Leiden Status should be considered in counselling about
her future method of contraception.
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Introduction
Ever since the first report in 1961,' the risk of venous
thrombosis has been a much debated hazard of the use of
oral contraceptives.2'3 Venous thrombosis has become less
common but has not disappeared with present-day low-
dose preparations.*-6 It is still unclear why oral
contraceptives cause thrombosis, and why they do so only
in a small number of women.
A hereditary abnormality in the protein C/protein S
anticoagulant pathway, which leads to increased
susceptibility to venous thrombosis, has been identified
lately.9 The abnormality is resistance to the anticoagulant
effect of activated protein C (APC-resistance). Activated
protein C inhibits clotting by cleavage of factors Va and
Villa, and APC-resistance is caused by a point mutation
at a cleavage site in factor Va which makes it inaccessible
to activated protein C.'° The mutation, a G/A Substitution
at nucleotide position 1691 of the factor V gene which has
been called factor V Leiden,10 has been confirmed by
others." It corresponds strictly with the presence of
hereditary APC-resistance.'2
We found APC-resistance in about 20% of patients
with venous thrombosis and 3-5% of a general population
sample in the Netherlands.12·" In a Swedish study, APC-
resistance was present in 33% of thrombosis patients and
5% of controls.14 These findings showed that APC-
resistance is a strong risk factor for venous thrombosis
and that it is much more prevalent than the other known
hereditary abnormalities of the anticoagulant pathway
that lead to increased risk of venous thrombosis (ie,
protein C, protein S, and antithrombin deficiency).
We have investigated whether the presence of the factor
V Leiden mutation could explain thrombosis in young
women who use oral contraceptives. Specifically, we
wanted to know whether the risk of thrombosis that exists
in oral-contraceptive users is increased in those who
carry the mutation. The investigation was pari of a
population-based case-control study on hereditary
factors in venous thrombosis, the Leiden Thrombophilia
Study."
Patients and methods
The design of our population-based case-control study has been
described previously." Consecutive patients younger than 70,
with an objective diagnosis of a first episode of deep venous
thrombosis between 1988 and 1993 and without an underlying
malignant disorder, were selected from the files of three
anticoagulation clinics in the Netherlands which monitor
anticoagulation treatment of virtually all patients in three well-
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Factor V Leiden mutatlon
present
Current OC use
No current OC use
Relative nsk (95% Cl)
Patients
25
10
50 (0 8-31 8)
Controls
2
4
No factor V Leiden mutatlon
Patients
84
36
3 7 (2 2-6 1)
Controls
61
100
OC=oral contraceptive
Table l Current use of oral contraceptlves among patients and
controls accordlng to presence of factor V Leiden mutation
defined geographical areas Controls were finends and
acquaintances, or partners of other patients, matched for age
and sex with the cases Patients and controls were seen between
1990 and 1993 (6 to 19 months after the acute event) by
one of us (TK) for an interview about nsk factors, physical
exarmnanon, and blood sampling for clottmg factor and DNA
analysis The presence of the factor V Leiden mutation was
shown by Mini digesnon of amplified factor V DNA and
visuahsanon of the cleavage products on ethidium-bromide-
stained agarose gels '°
For this invesüganon we selected from among our whole study
populauon women aged 15-49 We found 190 patients and 194
controls We excluded women who were pregnant (10), within 30
days post partum (14), or with a recent miscamage (2) at their
study index date (the date of the clinical thrombonc event in the
case, and the corresponding date for the control), we also
excluded postmenopausal women (31) and those who had used
only depot contraceptive preparanons (3) Thus, 155 patients
and 169 controls were left m the analysis
In most analyses we grouped homozygous and heterozygous
carriers of the factor V Leiden mutation We contrasted current
use of oral contracepnves dunng the month preceding the
thrombosis index date with non-use m that month Previous and
never use were grouped after we had venfied that oral-
contraceptive use that was stopped more than a month before the
thrombosis index date gave no excess nsk, which is m accordance
with the known acute effect of oral contraceptlves on venous
thrombosis
Although the onginal data were age matched, we present
analyses on unmatched data Undoing the matching permits
analysis of subgroups of cases and controls selected for variables
upon which they were not matched It also enables the
presentanon of the raw data A disadvantage is that the
unmatched analysis will diminish the contrast between the
groups, especially with respect to the effect of oral contraceptlves
Since, however, our analysis was already restncted to one of
the matching factors (sex) and partly restncted to the other
(age), we expect this attenuaüon to be shght We also expect
little anenuaaon of the effect of the factor V Leiden mutation,
smce its prevalence is hkely to be independent of age, except for
sample fluctuanon, because it is an autosomal genetic
abnormality "
Relative nsks of thrombosis among current users of oral
conrracepnves were esnmated äs odds ranos and their 95% CI
according to Woolf" To show the absolute effect of the
cumulauon of nsk factors, we also esnmated the populanon
incidence of thrombosis in young women with the four possible
combinanons of factor V mutation and use of oral contraceptlves
We esnmated the total number of person-years that had yielded
the cases and parunoned these person-years according to the
distnbuuon of pill use and the factor V mutation in the control
group Since we know that m our onginal study 117 female
patients aged 15-49 came from the Leiden anticoagulation climc,
which has a geographical source populanon of 109 824 m that
age group (data provided by the mumcipal admimstration), first
thrombosis incidence among young women without underlymg
disease in the Netherlands can be estimated over the 5 years of
our study äs 2 l in 10000 woman-years (l 17/[5X109 824])
Division of the number of women with venous thrombosis by the
proportional number of person-years in the categones of pill use
and carnage of the mutation (proportions taken from the control
group) gives estimates of the populanon incidences This
techmque was used in one of the first case-control studies on
smoking and lung cancer" and has since been refined " The
method shows whether more events occurred in the presence of
both factor V Leiden and oral-contraceptive use than would be
expected by the sum of the individual effects of each of these nsk
factors
We camed out logistic regression to assess the direction and
magmtude of the multiplicative interaction between recent use of
oral contraceptlves and the factor V Leiden mutation and to
evaluate the effect of controllmg for the matching factor age and
the effects of other potential nsk factors such äs smoking, obesity
(Quetelet index greater than 30 kg/m2), surgery in the month
before the thrombosis index date, and diabetes
Results
109 (70%) of the 155 women with first venous
thrombosis and no other underlymg disorder had been
usmg oral contraceptlves in the month before thrombosis
compared with 65 (38%) of the 169 controls This
amounts to an increase in nsk (relative nsk) of 3 8 (95%
CI 24-60) Of the 155 women with thrombosis, 35
(23%) carned the factor V Leiden mutation (5
homozygotes and 30 heterozygotes) compared with 6
(3 6%) controls (all heterozygotes) This leads to an
increase m nsk of venous thrombosis among carriers of
the factor V Leiden mutation of 7 9 (3 2-19 4) When the
analysis was restncted to heterozygotes, the relative nsk
was 6 8 (2 7-16 8)
The relative nsk of thrombosis associated with oral
contraceptlves was at least äs high in carners of the
mutation äs in women with the normal genotype (table l,
5 0 w 3 7) This result was similar after exclusion of the
homozygotes from the analysis (5 women, of whom 3
used oral contraceptlves, relative nsk 5 5 [0 84-36]) The
small difference in relative nsk between carriers of the
mutaDon and women with the normal genotype is
statistically uncertam, however, owmg to the small
number of control women with the factor V Leiden
mutation (only 6 women) As a first approximation,
therefore, we conclude that the relative nsk of thrombosis
due to current oral-contraceptive use is similar among
carners and non-camers of the mutation and does not
sigmficantly differ from the overall 4-fold relative nsk
associated with oral-contraceptive use However, the
presence of the mutanon itself causes a 7-8-fold increase
in nsk '°" This increase is also found for women in the
absence of oral-contraceptive use, of the patients who did
not use the pill, 10 carned the mutation and 36 did not
compared with 4 and 100 controls, a relative nsk of 7 0
(2 1-23 5) for the factor V Leiden mutanon in the
absence of oral contraceptlves The addmonal use of oral
contracepnves will multiply this 7-fold increase by 4, so
that a woman who uses oral contraceptlves and is a carner
of the mutation will have a nsk of venous thrombosis
about 30 times that of a non-user who does not carry the
mutation This can also be calculated directly from table
l by contrasting the relative frequency of havmg both nsk
factors versus none among patients and controls of the
patients, 25 had both nsk factors and 36 none, compared
with 2 and 100 among die controls (relative nsk 34 7
[78-154])
Since we know that first thrombosis in the absence of
underlymg disease has an approxirnate incidence of 2 l in
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Factof V Leiden negative
No OC use
Current OC use
Factor V Leiden positive
No OC use
Current OC use
Patlents
36
84
10
25
Person-years*
437 870
275 858
17515
8757
Incldence per
10 000 person-vears
08
30
5 7
285
*A total of 740 000 person years (yieldmg 155 patients) was partitioned accordmg to
the distribution of the control group 100/63/4/2
Table 2 Estimated population incidence of flrst venous
thrombosis in womon aged 15-49, accordlng to presence of
factor V Leiden mutation and use of oral contraceptives
10 000 person-years m this age group, we can calculate
that the 155 cases originale from a population of about
740 000 person-years The distribution of these person-
years over current use of oral contraceptives and factor V
Leiden carnage can be denved from the control group,
which is representative of the population from which these
cases ongmated " The incidence of thrombosis mcreases
from 0 8 per 10 000 women per year for non-users of oral
contraceptives without the mutation to 28 5 per 10 000
for those with the mutation who also use oral
contraceptives (table 2) The absolute increase in
thrombosis nsk due to oral contraceptives (ic, the nsk
difference) is much larger m women who carry the factor
V Leiden mutation than m women who do not In women
without the mutation, use of oral contraceptives yields an
addiüonal 2 2 cases per 10 000 women per year, whereas
among carners of the mutation oral contraceptives
increase the number of cases by 22 8 per 10 000 women
per year This finding indicates that the )omt effect of the
two nsk factors is more than additive
The increased nsk is seen when heterozygotes and
homozygotes are taken together and is the same for
heterozygotes only (the majonty of the patients with the
mutation) All 5 homozygotes were patients with deep
venous thrombosis and 3 were current users of oral
contraceptives However small the numbers, this
Proportion of oral-contraceptive use matches that in the
rest of the patients Homozygotes have a baselme
nsk of thrombosis 50-80 times that of non-carners,15
so even a smaller increase in thrombosis nsk by
oral-contraceptive use—eg, a relative nsk of 2—would
carry the cumulative relative nsk of homozygotes to more
than 100
We carried out logistic modelhng to assess several other
potential risk factors, the mfluence of control for the
matching factor age, and the interaction Recent surgery,
diabetes, and obesity were moderate to strong
independent nsk factors, smoking carried no extra nsk of
deep venous thrombosis The small numbers of women
with diabetes and recent surgery (2 and 17) led to
inefficient fittmg of the logistic model Obesity had a
small independent effect As expected, statistical
adjustment for age increased the estimates The followmg
relative nsks were obtamed in a logistic model with fine
stratification for age (entered in years) current use of oral
contraceptives 60 (34-106) and factor V Leiden
mutation 9 3 (3 6-24 1) With a multiplicative interaction
term between oral contraceptive use and factor V Leiden
mutation, the relative nsks became 58 (32-105), 81
(2 3-28 2), and l 2 (0 2-9 7) for the multiplicative
interaction The analysis confirmed a near-multiplicative
effect of oral contraceptive use and factor V Leiden
mutation, smce the relative nsk for the interaction in this
multiplicative model remamed close to l 0
Discussion
The combination of the use of oral contraceptives and
carnage of the factor V Leiden mutation strongly
mcreases the nsk of venous thrombosis The combmed
effect of these nsk factors seems close to a multiph-
cation of the separate relative risks In terms of absolute
effect, however, this means that the nsk of venous
thrombosis among women who use oral contraceptives is
much greater when they carry the factor V Leiden
mutation
Carnage of the factor V Leiden mutation and APC-
resistance led to a 7-8-fold increase in venous thrombosis
risk in our study in the Netherlands10'3 A Swedish
estimate was somewhat higher (10 [4 0-25 0],
recalculated from Svensson and Dahlback14) The
difference is possibly due to differences in patient
samples—a proportion of the patients in the Swedish
study had recurrent or famihal thrombosis
Current oral-contraceptive use in our study gave a close
to 4-fold nsk, which increased to 6-fold after adjustment
for age These estimates are similar to those of the few
studies that have specifically addressed the nsk of venous
thrombosis among women usmg modern low-dose oral
contraceptives, which were also predommant in the
Netherlands durmg our study penod The Oxford Family
Planmng Study4 found a relative risk of 6 5 (l 2-16 2,
recalculated), the Füget Sound study45 2 8 (0 9-8 2), and
a study m Boston7 8 l (3 7-18), with no indication of a
decreased risk m the lowest dose group The confidence
intervals from these studies are wide and overlapping,
because of the small numbers Older studies on high-dose
pills had relative risk estimates between 2 and 11"
Several of these older investigations used only a clinical
diagnosis of venous thrombosis, which is now known to
be highly unreliable with misclassification rates of up to
50% 2021 In studies with comparable diagnostic criteria,
however, low-dose preparations confer less risk than the
older high-dose pills 4 *s
In our study the multiplication in risk caused by oral
contraceptives was of similar magnitude in camers and
non-carners of the factor V Leiden mutation Therefore
our present best estimate is a cumulative 30-fold increase
for oral-contraceptive users who also carry the genetic
risk By a similar multiplicative effect, the risk increase for
homozygotes is more than 100-fold " A difficulty in the
Interpretation of our data is that the confidence interval of
the relative risk of oral-contraceptive use among carners
of the factor V Leiden mutation is large, mainly because
of the small number of women without thrombosis who
carry the mutation (table 1) To obtain a more rehable
estimate we would need a study with larger numbers of
controls positive for factor V Leiden Smce the prevalence
of factor V Leiden in the general population is 3-5%, a
case-control study several times larger than this one
would be needed However, we can offer two other and
different approximations to estimate the use of oral
contraceptives among women who carry the mutation
The proportion of such women usmg oral contraceptives
should not differ too much from that in the general
population, smce it is unlikely that a hitherto unknown
mutation would mfluence the use of contraceptives,
especially in women who have not yet had a thrombosis
Therefore, a more stable estimate can be obtamed by
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companng the use of oral contraceptives between factor-
V-positive thrombosis patients (25 vs 10) and the total
control group of our study (65 vs 104) This yields a
relative nsk of 4 0 (l 8-8 9), which is slightly higher after
age stratification This estimate is strengthened by a
companson with independent population data from the
Netherlands In repeated health surveys by the
Netherlands Central Bureau of Statistics for the years
1989, 1990, and 1991 (corresponding to our study), the
frequency of oral contraceptive use among women aged
15 to 49 was 377%, 342%, and 406% (random
population samples of size 2245, 1971, and 1865) z'
These percentages are close to what is found among our
population controls and also yield relative nsks of about
4 0 for thrombosis patients positive and negative for factor
V Leiden, which also mcrease on age stratification
A feature of our study is the use of fnends and
acquamtances of the affected women äs controls (for
about 60% of the patients"), and partners of other
patients when a woman did not volunteer a fnend This
practice may dimmish the contr?st between the patients
and their controls, since fnends might share life-style
charactenstics such äs use of oral contraceptives If
anythmg, the effect would be to dimmish the relative nsk
It is reassuring that the Overall use of oral contraceptives
among our control group is close to that of the general
population of the Netherlands It seems very unlikely that
the method for selection of controls affected the estimates
for the genetic effect When the age matching is taken into
account m a logistic model, all relative risk estimations
become higher We do not want to emphasise any of these
higher estimations whose cumulation would lead to a
more than 50-fold mcrease, since they rest on model
assumptions and might depend on subgroup sample
fluctuations
Our analysis leads to the conclusion that the absolute
mcrease m risk due to oral contraceptives is larger in
women who carry the factor V Leiden mutation than in
those who do not This difference is most clearly seen by
approximate back-calculation to population incidence
rates (table 2) Although such calculations are
hypothetical, and rest on general assumptions, they offer
insight into the absolute effect (ic, the nsk difference)
when oral contraceptives are used in woman with and
without the genetic defect The difference m risk brought
about by oral contraceptives in women who do not carry
the mutation is about 2 2 per 10 000 woman-years, while
the risk difference for the mutation m the absence of oral-
contraceptive use is about 4 9 per 10 000 The combmed
presence of the mutation and oral-contraceptive use gives
a risk difference of about 27 7 per 10 000 woman-years,
which is much larger than the sum of the individual
effects Thus, in the presence of both risk factors, venous
thrombosis develops in a substantial number of women
who would never have had thrombosis m the presence of
either risk factor alone "" They developed thromboses
only because both nsk factors were present In this
reasonmg it is not important to know whether or not the
relative nsks are exactly multiplicative, it is the additional
number of cases of thrombosis, over and above the sum of
the individual effects, that is counted
The biological Interpretation follows from the same
reasonmg The consequences of the factor V Leiden
mutation (APC-resistance) and the metabolic changes m
the clotting cascade due to oral contraceptives probably
enhance each others' effects This idea finds support in
the strong absolute mcrease in venous thrombosis nsk
dunng oral-contraceptive use in a large protem-C-
deficient kindred24 and m case-reports of severe
thrombosis in young oral-contraceptive users with protem
S and antithrombin deficiency25 M These deficiencies,
which are very rare m the general population, lead to a
defect in the anticoagulant part of the clotting cascade
that is functionally similar to APC-resistance
Whatever the ultimate biological explanation, it is clear
that a young woman who Starts usmg oral contraceptives
is at a higher nsk of venous thrombosis if she carnes the
factor V Leiden mutation Should young women who
Start usmg oral contraceptives be screened for the
mutation and the resulting hereditary APC-resistance' It
is difficult at this stage to propose a balance of benefits
and nsks About 4% of young women would be denied
oral contraceptives if factor V Leiden mutation became a
contramdication The absolute risk of deep venous
thrombosis is low even among young women who have
both risk factors Most episodes among the young are
minor, although pulmonary embohsm does occur
Withholding oral contraceptives from all carners might be
a high pnce to pay, especially since other methods of
contraception are more error-prone and cause greater
medical, psychological, and social morbidity Although it
might be tempting to screen for homozygotes, who have a
greatly mcreased nsk, such an undertaking would not be
cost-effective since the population frequency of
homozygosity of the factor V Leiden mutation is only
about l in 5000 15
When a young woman has had venous thrombosis,
however, her factor V Leiden Status might be take into
account in counsellmg about future methods of
contraception If she is a homozygote, she should be
strongly advised to discontmue oral contraception If she
is a heterozygote, the mcreased risk should be clearly
explamed, since her thrombosis episode shows that she
might be one of the women who are susceptible to the
mterplay between oral contraceptives and hereditary
APC-resistance In addition, other environmental or
hereditary mechanisms might be at play, such äs
combined genetic defects (eg, protem C deficiency
combmed with factor V Leiden) " This combination
might result in relative nsks that approximate those of
homozygosity for the factor V Leiden mutation If
screening for factor V Leiden is done m a young woman
with an objective diagnosis of venous thrombosis, it makes
good sense to investigate also protem C, protem S, and
antithrombin deficiency28 The result of screening for
genetic risk factors might also have a beanng on
contraceptive decisions of the patient's mother and sisters,
and for possible anticoagulation prophylaxis at other times
of high nsk such äs dunng immobihsation or post
partum At first or repeat prescnption of oral
contraceptives, it might pay to take a thorough personal
and family history of thrombosis and to investigate if
positive 2"
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